Nuvalent, Inc. (NUVL)
102.70
+2.48
(+2.47%)
USD |
NASDAQ |
Mar 04, 15:57
Nuvalent Research and Development Expense (Annual) : 306.97M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Glaukos Corp. | 150.61M |
| Edgewise Therapeutics, Inc. | 149.30M |
| Neurocrine Biosciences, Inc. | 1.016B |
| Vanda Pharmaceuticals, Inc. | 109.27M |
| Kodiak Sciences, Inc. | 126.10M |